TO THE EDITOR
Down's syndrome (DS) children have the 10-to 20-fold increased risk of developing acute leukemia compared with non-DS children. Acute myeloid leukemia (AML) in DS children shows unique characteristics as to be a predominance of the megakaryoblastic leukemia (AMkL) and a preceding history of the transient myeloproliferative disorder (TMD), whose blasts are morphologically and phenotypically indistinguishable from those of AMkL. TMD is developed in about 10% of DS infants and resolves spontaneously in most cases. However, 20% of TMD cases develop AMkL within 3 years, suggesting that additional genetic alterations might occur during the progression from TMD to AMkL. Recently, somatic mutations of the GATA1 gene were reportedly associated with AMkL of DS children. 1 In addition, it was reported that GATA1 mutations were present in the TMD blasts, and that the identical GATA1 mutation was found in sequential samples collected from a patient during TMD and subsequent AMkL. [2] [3] [4] [5] These results suggested that GATA1 mutations are an early event in DS leukemogenesis and contribute Correspondence to both pathogenesis of TMD and AMkL, while the acquisition of additional genetic alterations might be necessary for the progression from TMD to AMkL. To date, a lot of genetic alterations, which are involved in the pathogenesis of leukemia, have been accumulated. Especially, mutations of FLT3, N-RAS, p53 and cKIT genes are frequently found in AML, and likely to be associated with the disease progression. To examine whether these mutations are involved in the progression of TMD to AMkL, we comprehensively analyzed these mutations in AMkL and TMD of DS. The study population included 14 AMkL and four TMD cases of DS. The diagnosis of AMkL and TMD was based on morphology, histopathology, the expression of leukocyte differentiation antigens and/or the French-American-British classification. The diagnosis of DS was confirmed by the conventional cytogenetic analysis. Bone marrow samples from the patients with AMkL and TMD were subjected to the FicollHypaque (Pharmacia LKB, Uppsala, Sweden) density-gradient centrifugation and cryopreserved in liquid nitrogen before use after obtaining informed consent from all parents of the patients. High-molecular weight DNA was extracted from the samples by the standard method. For screening of GATA1 mutations, we amplified genomic DNA corresponding to exon 2 of GATA1 by polymerase chain reaction (PCR) using the primers: forward primer, 5 0 -GGATTTCTGTGTCTGAGGACC-3 0 and reverse primer, 5
0 -CAAGACAGCCACTCAATGGAG-3 0 . Amplified products were cloned into pGEM-T Easy vector (Promega, Madison, WI, USA) and sequenced on a DNA sequencer (310; Applied Biosystems, Foster City, CA, USA) using a BigDye terminator cycle sequencing kit (Applied Biosystems). FLT3 gene mutations of internal tandem duplication of the juxtamembrane domain (FLT3/ITD) and in the activation loop (FLT3/D835Mt), N-RAS gene mutations of codons 12, 13 and 61 and p53 gene mutations of exons 5-8 were examined as previously reported and were confirmed by the sequencing procedure. [6] [7] [8] To detect mutations at D816 within the activation loop of the cKIT gene, we amplified exon 17 of the cKIT gene by genomic PCR using the forward primer, 5 0 -CCTCCAACCTAATAGTGTA-3 0 and the reverse primer, 5 0 -TCCTTTAACCACATAATTACAATCAT-3 0 , and amplified products were directly sequenced.
Mutations of GATA1 were found in all AMkL and TMD cases and clustered within the first coding exon (exon 2) consistent with previous reports (Table 1) . Each of the mutations from 11 cases was an insertion or a deletion, which altered the reading frame of GATA1 resulting in the introduction of a premature stop codon. Five mutations were missense mutations; one mutation resulted in a stop codon and two mutations resulted in a loss of the first initiation codon. To evaluate additional gene mutations in DS AMkL, we analyzed mutations in FLT3, N-RAS, p53 and cKIT genes. p53 mutations were found in two of 14 AMkL and one of four TMD cases, although no FLT3, N-RAS and cKIT mutation was found in all AMkL and TMD cases (Table 1) .
In this study, we comprehensively analyzed the gene mutations, which were commonly found in AML, although we could not define the specific gene mutations related to the evolution from TMD to AMkL of DS. Since cKIT mutations in AML were restrictedly found in core-binding factor leukemias, no mutations in AMkL were well acceptable. 9 Mutations of FLT3 and N-RAS are so far the most frequent gene alterations reported to be involved in AML. An incidence of FLT3 mutations is apparently associated with the age of patients with AML, 7 although its association of N-RAS mutations has not been demonstrated. FLT3/ITD has been found in approximately 20% of adult patients, but in 34% of patients over 55 years of age. In contrast, it has been found in only approximately 10% of childhood patients. Furthermore, it has been found in only one of 23 (4.3%) infant AML patients under 1 year of age. The association of FLT3/D835Mt with aging remains unclear, while our study showed that it was found in 44 of 713 (6.2%) adult patients and four of 100 (4%) childhood patients with AML. These results indicated that the absence of FLT3 mutations in TMD and AMkL of DS is likely to be related to the lower age of patients. It was reported that p53 mutations might be involved in the evolution from TMD to AMkL, because two of three AMkL harbored p53 mutations, but all seven TMD did not. 10 However, we could not demonstrate the relationship between the evolution of AMkL and p53 mutations. Mutations of GATA1 and p53 genes in AMkL and TMD patients with DS are shown. GATA1 mutations were found in all AMkL and TMD cases. All GATA1 mutations were clustered within exon 2.p53 mutations were found in two of the 14 AMkL cases and one of the four TMD cases. No FLT3, N-RAS and c-KIT mutation was found in all cases. NA, not applicable.
